Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
Date: April 24, 2017
Issue #:
1519Summary:
The FDA has approved dupilumab (Dupixent– Sanofi/Regeneron), a subcutaneously-injected fully human
monoclonal antibody, for treatment of adults with
moderate to severe atopic dermatitis (eczema) that
has not responded to topical therapies. It can be used
with or without topical corticosteroids.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Antibacterials Atopic dermatitis corticosteroids crisaborole Cyclosporine dupilumab Dupixent Elidel Eucrisa Phototherapy Pimecrolimus Protopic Tacrolimus Source Type: research
More News: Corticosteroid Therapy | Dermatitis | Dermatology | Drugs & Pharmacology | Eczema | Elidel | Prograf | Restasis | Tacrolimus